Oncology and hematology are extremely complex, crowded and chaotic therapeutic areas.
Manufacturers of these high-science brands are often faced with:
- Unprecedented pressure to accelerate their speed to market,
- Securing patient access and affordability,
- Creating compelling stakeholder engagement in a hybrid world,
- Changing patient journeys
- Evolving FDA interactions,
- And much more.
The first five years of commercialization typically costs $265M. Manufacturers should not be forced to lose ownership, sacrifice their company value or invest more than $200M to commercialize on their own. Instead, they must decide how to develop the necessary infrastructure to launch, shape the market and build industry relationships.
